Combination of Platelets Rich Plasma and Hyaluronic is an Effective Tool for Treatment of Knee Osteoarthritis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- visual analogue scale
研究概览
简要总结
The purpose of the study is to determine the effects of HA, PRP and the combination of HA and PRP in reducing pain and improving functional disability in patients with knee osteoarthritis.
详细描述
To determine the effects of combination of platelet rich plasma (PRP) and hyaluronic acid and the PRP or HA alone in reducing pain and increasing range of motion among individuals with knee osteoarthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
Single blinded study, only the assessor was kept blinded
入排标准
- 年龄范围
- 40 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •grade II-III according to the Kellgren-Lawrence classification),
- •pain or functional limitations in patients' activity of daily living before the treatment,
- •age between 40 and 70 years of age, and the absence of clinical or imaging signs of articular instability.
排除标准
- •includes known hypersensitivity to hyaluronic acid,
- •pregnancy and lactation, a BMI greater than 40 kg/m2,
- •chronic administration of anticoagulant drugs or a history of coagulopathies,
- •neoplastic lesions, and knee or kidney failures
研究组 & 干预措施
Group A
Hyaluronic acid
干预措施: Hyaluronic Acid (HA) (Drug)
Group B
platelet rich plasma
干预措施: Platelet Rich Plasma (Drug)
Group C
Hyaluronic acid and platelet rich plasma
干预措施: Hyaluronic Acid (HA) and Platelet rich plasma (Drug)
结局指标
主要结局
visual analogue scale
时间窗: Recorded before the treatment and repeated within 3 and 6 months after the treatment.
It is a straight line, 100 millimeters long line, one end of the line means "not at all" or "none" and the other end means "the worst possible" or "extremely".
次要结局
- Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)(Recorded before the treatment and repeated within 3 and 6 months after the treatment.)
研究者
Dr Ranjeet Kumar
Principal investigator
University of Karachi